

IL-1 production inhibitor.

20. A method of treating a clinical condition requiring immunosuppression, which method comprises administering to a patient in need thereof a therapeutically effective amount of a compound as defined in claim 1.

21. A method according to claim 20 wherein said clinical condition is an immunoinflammatory condition.

22. A method according to claim 21 wherein said immunoinflammatory condition is selected from the group consisting of rheumatoid arthritis, osteoarthritis, septic shock, psoriasis, atherosclerosis, inflammatory bowel disease, Crohn's disease and asthma.

23. A method according to claim 20 wherein said clinical condition is a central nervous system disorder.

24. A method according to claim 23 wherein said central nervous system disorder is selected from the group consisting of encephalomyelitis and Alzheimer's disease.--

REMARKS

Basis for the new claims is provided in the specification as follows.

<u>Claim</u>	<u>Basis</u>
18	page 11 lines 19-22
19	page 11 line 22
20	page 11 lines 23-24
21	page 11 line 25 and page 12 lines 2-3
22	page 12 lines 2-5